Vidhya Pharmachem Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
- Paid Up Capital ₹ 7.01 Cr
- Company Age 25 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 188.55 Cr
About Vidhya Pharmachem
Vidhya Pharmachem Private Limited (VPPL) is a Private Limited Indian Non-Government Company incorporated in India on 11 August 1999 and has a history of 25 years and five months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 7.01 Cr.
The company currently has active open charges totaling ₹188.55 Cr.
Mahesh Avalani and Meet Bhadra serve as directors at the Company.
Company Details
-
Location
Mumbai, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U99999MH1999PTC121241
-
Company No.
121241
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
11 Aug 1999
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Vidhya Pharmachem?
Board Members (2)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Mahesh Avalani | Director | 11-Nov-2022 | Current |
Meet Bhadra | Director | 11-Nov-2022 | Current |
Financial Performance of Vidhya Pharmachem.
Vidhya Pharmachem Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
|
||||||
Revenue from Operations |
|
||||||
Total Assets |
|
||||||
Profit or Loss |
|
||||||
Net Worth |
|
||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Vidhya Pharmachem?
In 2023, Vidhya Pharmachem had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹188.55 Cr
₹0
Charges Breakdown by Lending Institutions
- Union Bank Of India : 70.75 Cr
- Bank Of Baroda : 65.20 Cr
- Oriental Bank Of Commerce : 20.30 Cr
- Axis Bank Limited : 20.00 Cr
- Sbi Global Factors Limited : 10.00 Cr
- Others : 2.30 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
16 Aug 2012 | Bank Of Baroda | ₹2.00 Cr | Open |
17 Jun 2011 | Sbi Global Factors Limited | ₹10.00 Cr | Open |
08 Jun 2011 | Oriental Bank Of Commerce | ₹20.30 Cr | Open |
01 Jun 2011 | S. E. Investments Limited | ₹1.00 Cr | Open |
20 Aug 2010 | Axis Bank Limited | ₹10.00 Cr | Open |
How Many Employees Work at Vidhya Pharmachem?
Unlock and access historical data on people associated with Vidhya Pharmachem, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vidhya Pharmachem, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vidhya Pharmachem's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.